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Abstract
We study the effect of ageing, defined as an extra year of life, on health care
utilisation. We disentangle the direct effect of ageing, from other alternative
explanations such as the presence of comorbidities and endogenous time to
death (TTD) that are argued to absorb the effect of ageing (so-called ‘red her-
ring’ hypothesis). We exploit individual level end of life data from several
European countries that record the use of medicine, outpatient and inpatient
care and long-term care. Consistently with the ‘red herring hypothesis’, we
find that corrected TTD estimates are significantly different from uncorrected
ones, and their effect size exceeds that of an extra year of life, which in turn is
moderated by individual comorbidities. Corrected estimates suggest an overall
attenuated effect of ageing, which does not influence outpatient care
utilisation. These results suggest the presence of ‘more than one red herring’
depending on the type of health care examined.
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1 | INTRODUCTION
Population ageing is commonly portrayed as a central determinant of health care (HC) spending (Marino, Morgan,
Lorenzoni, & James, 2017; WHO, 2015).1 Given that the percentage of old age population in the countries of the Organi-
sation of Economic Cooperation and Development (OECD) is projected to rise to 25% by 2050 (Lafortune &
Balestat, 2007), it is important to understand how ageing affects HC use. However, there are good reasons to argue that
the effect of ageing on health expenditure is overestimated. One of the main explanations is that a significant share of
expenditures take place around the time of death. Some studies even go as far as to argue that the effect of ageing on
1In 2012 and 2013, the percentage of health care expenditure concentrated in the cohort aged 65 and older ranged between 38.8% in the Czech
Republic and 46.7% in Germany (European Union, 2016).
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HC reflects a ‘red herring’, given that when time to death (TTD) is accounted for, the effect of ageing disappears
(Zweifel, Felder, & Meiers, 1999; Zweifel, Felder, & Werblow, 2004; Hall & Jones, 2007; Shang & Goldman, 2007).2
In addition to the consideration of TTD, which is potentially endogenous, another source of overestimation
(of ageing effects on health expenditure) results from the correlation between morbidity and an individual's age,3 as it
is subject to omitted variable bias. The effect of such omitted variable bias can be analysed using individual longitudinal
data which captures the influence of early lifestyles. This paper addresses some of these econometric concerns by draw-
ing on individual data that can explain both individual- and country-level variation in morbidity and TTD.
Finally, another potential red herring, results from the fact that ageing can change the composition of HC towards a
more intense use of end of life care, hospital care and long-term care (LTC).4 Hence, the effect of ageing is likely to be
heterogeneous across different types of HC, which especially differ in their reliance on technology (Breyer, Costa-Font,
& Felder, 2010). Finally, ageing can incentivise the utilisation of new technologies that specifically cater to the HC
needs of an ageing population.5 Hence, it is important to understand how it impacts on different types of HC
(e.g., medicines, hospital care and home care).
This paper examines the effect of ageing on different types of HC use and disentangles the effect of other con-
founding effects, namely, (a) proximity to death, (b) comorbidities and lifestyles and (c) differences in the composition
of HC. Previous research,so far, has been country-specific and mainly relies on cross-sectional insurance data records,
often limited to hospital care. We exploit longitudinal end of life data that covers a long list of European countries for
the period 2004–2017 included in the Survey for Health, Ageing and Retirement in Europe (SHARE). The advantage of
using a multi-country individual level panel is, that it allows for the inclusion of both individual and country fixed
effects that net out both institutional and individual specific explanantions for differences in the effect of ageing on HC
use, and by extension on health care expenditures (HCE). SHARE contains an end of life module that identifies the
cause of death of the individual which allows identifying deceased (and survivor) individuals, namely, those that have
died between two consecutive waves. We report both parametric and non-parametric estimates, and address the prob-
lem of endogeneity of TTD by correcting the estimations with rich instruments for parental survival, available in the
dataset.
Our findings suggest that corrected TTD estimates are significantly different from uncorrected ones, and affect both
the extensive and intensive margin of hospital admissions and length of stay, as well as home and nursing home care
use, consistently with the ‘red herring hypothesis’. Second, the effect size of TTD exceeds that of ageing, which in turn
is attenuated by the presence of comorbidities. Finally, we find that ageing does not explain (both the internal and
external margins of) outpatient visits with doctors and nurses once TTD and comorbidities are controlled for.
The structure of the paper is as follows. Section 2 reviews the most relevant literature. Next, we describe the data
and empirical exercise. Sections 5 and 6 contain the results, and Section 7 concludes.
2 | RELATED LITERATURE
2.1 | Red herring hypothesis
The effect of ageing on health spending has been brought to question based on the fact that age is correlated with mor-
tality. A seminal study used a sample of deceased patients from a Swiss sickness fund and found that the effect of age
on HC expenditure disappears once the effect of TTD is netted out (Zweifel et al., 1999)6. This opened a long list of con-
tributions to the question of ageing and health spending, and this paper aims to add value to the same endeavour.
2In fact, the effect of TTD decreases with age (Felder et al., 2010), and Seshamani and Gray (2004) have shown that hospital expenditures increase
well over 15 years before death, and decline once an individual's turns 80, hence casting doubts about the effects of age on health care expenditures.
3Consistently, Dormont et al. (2006) establish, using French, data that the compression of morbidity offsets the potential effects of ageing in health
spending. Similarly, Howdon and Rice (2018) find that the effect of chronic conditions weakens the effect of ageing on hospital expenditures.
4This puts the coordination of health and long-term care services at the centre stage (Costa-Font, Jimenez-Martin, & Vilaplana, 2018).
5Consistently, Goldman et al. (2005) using United States data and Wong et al. (2012) using Dutch data, found that medical innovations give rise to a
differential shift of health expenditures to older age groups.
6That said, given that Zweifel et al. analyze only decedents, one would expect the effect of age on HCE to be negative. Hence, Breyer and Lorenz
(2020) suggest that a null effect does not prove the point they want to make. This requires examining evidence for survivors. Which is a point we
come back later.
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2.2 | Econometric specifications
Almost all estimates of the effect of ageing on health expenditure have received a significant deal of criticism due to a
series of econometric issues, mainly omitted variable bias, and the potential reverse causality of TTD estimates (Salas &
Raftery, 2001; Seshamani & Gray, 2004). The logic is that if HC investments (e.g., such as new drugs) improve patient's
health status, they could extend life. Therefore, estimates that fail to account for the dynamic influence of current and
previous health expenditures on life expectancy would overestimate the effect of ageing on HC use. In a later study,
Zweifel et al. (2004) confirmed his previous results after restricting the sample to a single year to ensure that HCEs only
affect the probability of survival in cases in which individuals are close to death, and considered both survivors and
deceased individuals in the sample. The results confirmed that age is not a significant variable in explaining the HCEs
of the deceased and, in the case of survivors, the effect of age is much lower when the TTD variable is controlled for.
For their part, Seshamani and Gray (2004) conclude that the omission of TTD from the analysis was found to over-
estimate the effect of ageing, and the number of trimesters before death is a significant explanatory variable, and its
impact on cost is found to be higher at the end of life.
Other more recent estimates suggest that TTD accounts for 16.7% and 24.5% of lifetime HC and LTC expenditures
(French et al., 2017). Similarly, Breyer, Ihle, and Lorenz (2017) estimate that HCEs in the last 4 years of life, account
for20% of total expenditures over a lifetime when accounting for changes in life expectancy (Breyer, Lorenz, &
Niebel, 2012). Hence, it seems TTD is not the only red herring underpinning the effects of ageing on HCEs.
2.3 | Endogeneity
TTD is likely to be affected by both reverse causality and omitted variable bias. Stearns and Norton (2004) use data from
the Medicare Current Beneficiary Survey (1992–1998) to document evidence of omitted variables, which is accounted
for by adding individual specific fixed effects, and corrects the effect of unobserved time-invariant characteristics. How-
ever, such strategy does not deal with reverse causality. An alternative strategy lies in employing instrumental variables
analysis, namely, exploiting the effect of a variable influencing health expenditure only via TTD, but not the age at
which the individual is interviewed (Steinmann, Telser, & Zweifel, 2007). This is important, given that OLS estimates
are biased if HCE and medical innovations prolong life (Lichtenberg, 2012).7 Felder, Werblow, and Zweifel (2010)
address the problem of endogeneity using an instrumental variable strategy that employs lags as instruments. They doc-
ument that TTD and its square retain their explanatory power in explaining HCE in its intensive and extensive margin.
However, as they themselves recognise, they are not able to fully purge TTD of its endogeneity, given that when errors
are AR(1) distributed, the parameter is not estimated consistently from a lagged instrument.8
2.4 | Heterogeneity
Although most of the literture focuses on the effect of ageing on inpatient care9, there are reasons for ageing to exhibit
heterogeneous effects across different types of HC, especially among health care services that differs in its reliance on
technology. Werblow, Felder, and Zweifel (2007) eluded the problem of endogeneity and focused on relating individual
HCE in a given year with the remaining TTD. They document evidence of heterogeneous effects as the majority of the
HCE components (drugs, hospital outpatient and hospital inpatient) are found not be influenced by age, but by TTD.
The most significant exception is acute care provided to patients who also receive LTC regardless of their survival
chance. They explain these results through the fact that patients with limited survival prospects attract a large share of
medical technology. Finally, Kelley et al. (2013) estimates that the increase in out-of-pocket expenditure in the last
years of life shows wide variability, which is explained by the increasing share of out-of-pocket expenditure that results
from dementia or Alzheimer's diseases,which is more than double that of gastrointestinal diseases or cancer.
7There is a literature examining the effect size, namely, whether it is small (months rather than years). Lichtenberg et al. (2012) estimates that
between 1991 and 2004, increased life expectancy by 0.62–0.71 years resulting from imaging technology, 0.96–1.26 years from use of newer outpatient
prescription drugs and 0.48–0.54 years from the use of newer provider-administered drugs.
8The two instruments (predicted TTD obtained from an auxiliary regression and accident insurance) pass the test for the overidentifying restrictions,
but the Hausman test rejects the null hypothesis for exogeneity for TTC.
9With some exceptions such as Atella and Conti (2014).
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2.5 | Technology and ageing
One interpretation of the effects of ageing on HCE is that technological progress is geared more intensively towards
older age cohorts (Breyer et al., 2010). Consistently, Goldman et al. (2005) from the United States as well as Wong,
Wouterse, Slobbe, and Boshuizen (2012) from the Netherlands concluded that most medical innovations have shifted
health expenditures to older age groups. Similarly, Dormont and Huber (2006) used microsimulation techniques to ret-
rospectively evaluate the components of a drift in the age profile of HCE during 1992–2000. They observed that the
impact of a change in clinical practice (12.9%) was 3.8 times higher than the increase in HCE. Therefore, technological
progress was possibly geared more towards older age cohorts—in this case, the impacts of changes in practices would
increase with age. In contrast, Breyer et al. (2012) found that expenditure in the last year of life tends to decrease and
they interpret there effect as revelaing a preference of physicians to treat more aggressively patients as their life expec-
tancy increases (controling for age and the relevant diagnoses).
2.6 | Morbidity and health spending
The effect of morbidity on health expenditure and utilisation is well established. Geue, Lorgelly, Lewsey, Hart,
and Briggs (2015) examined hospital spending data from individuals in the last 3 years of life using data from
Scotland for a period of 35 years. They document that costs of younger cohorts (less than 65 and 65–69 years)
exceed those of their last 11 quarters of life. Atella and Conti (2014) using primary care data from Italy, report
higher costs among those groups aged 70–79 than the eldest cohort. TTD coefficients suggest that 14 quarters
remaining before death positively affect primary care costs although the variation between the 14th and the 10th
quarter of age, is not significant. In contrast, primary care costs at 8 quarters before death steadily increase by
50% between the age of 45 and age 75. Similarly, Dormont, Grignon, and Huber (2006) estimates suggest that
changes in spending for a given morbidity were almost four times higher than the equivalent changes in the
structure of the population (+3.4%).10 Importantly, Ishizaki, Shimmei, Fukuda, et al. (2016) document a negative
effect of age on the probability of hospitalisation and no significant effect of age on length of stay at hospital
exists 3 months prior to death. Consistently, Howdon and Rice (2018) found that when morbidity is controlled
for, it absorbs two-thirds of the effect of TTD on HCE, which confirms the underestimation of the TTD effect
when the potential endogeneity of this variable is not taken into account.11
2.7 | Ageing and LTC substitution
Finally, a set of studies examine the relationship between age and LTC controlling for TTD. De Meijer, Koopmanschap,
d'Uva, and van Doorslaer (2011) analysed the use of institutional LTC and home care from a Dutch dataset of individ-
uals 55 years and older. They observed that once the effect of age was controlled by disability and morbidity, it
remained significant, but TTD was no longer significant. Similarly, Larsson (2008) documents that whilst age is a signif-
icant variable in predicting the probability of receiving formal home care, TTD explained the probability of
hospitalisation. Both predict the use of nursing home care.12 A final set of studies includes Karlsson and Klohn (2011)
addressing the problem of the endogeneity of TTD using instrumental variables, and Karlsson and Klohn (2014) which
show that TTD dives the use of institutional care whilst age was more important for home care use.
10Other similar studies are Payne, Abel, Guthrie, and Mercer (2013) who analysed hospital admissions among people aged 20 and over in Scotland
and found that the presence of physical multimorbidity was strongly associated with a higher probability of hospitalisation, especially related to
diagnosed mental health conditions. Palladino, Lee, Ashworth, Triassi, and Millet (2016) found a positive and significant relationship between the
number of chronic diseases and the use of primary, specialised and hospital care, and Schneider, O'Donnell, and Dean (2009) found a positive
relationship between the use of Medicare fee-for-service without institutional claims and the number of chronic diseases.
11Carreras, Ibern, and Inoriza (2018) using Spanish data document that the inclusion of morbidity controls reduced the effect of TTD up to 92%.
12More specific drawing on two instruments: (a) the absolute value of the difference between the mortality of men and women being 80 years and
older divided by the total population of this age group and (b) the aggregate of this year's and next year's mortality rate of the middle-age population
(25–55 years). The estimations show that age still has a strong impact on costs even after controlling for mortality rates and that the impact of TTD is
driven by the youngest cohort (70–74 years).
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3 | THE DATA AND DESCRIPTIVE ANALYSIS
3.1 | Longitudinal dataset
We use data from Survey of Health, Ageing, and Retirement in Europe (SHARE) corresponding to waves 1, 2,
4, 5, 6, and 7.13 Our variation originates from representative samples of individuals aged 50 years or above and
observed during 13 years (2004–2017). We exploit a cross-country variation of 17 countries, a potential sample of
288,555 individual observations. The following steps were taken to retrieve our sample (see Table 1). First, only
individuals who were observed for at least two consecutive waves were selected. This requirement allows us to
determine accurately if the individual living status in the subsequent wave is either survivor or deceased.
Individuals who are only interviewed once are discarded because we cannot be sure of their living status in the
subsequent wave. In the robustness checks section, we study the effect of attrition in detail, and document it has
no effect on our estimates. The final sample contains 156,979 observations corresponding to 54,549 individuals
(51,789 survivors and 2,760 deceased).
3.2 | Sample description
Table 2 reports the descriptive statistics for the different dependent variables examined both in the extensive and inten-
sive margins. Although a high percentage of zeros is observed for some HC types (hospitalisal stays, stays in other HC
facilities, nursing homes, and formal personal care), we observe a high the duration or intensity in the provision of
these services suggesting evidence ofoverdispersion. The destribution of outpatient visits (with a doctor or nurse), and
the consumption of prescription drugs, reveals a high probability of an outpatient visit (89% and 75% respectively) in
the last year (or the probability of consuming at least one medication), but such variables exhibit evidence of
overdispersion too.
The Table SA1 breaks down the descriptive statistics, differentiating between survivors and deceased. The percent-
age of deceased individuals in the 85+ age cohort is six times higher than that of survivors (25.17% vs. 3.65%). There is
a higher percentage of men and individuals who have only completed primary education in the deceased subsample
than in the survivor subsample. The deceased sample exhibits lower income and wealth (even adjusted for household
size). However, due to the differences between survivors and deceased being largely time invariant, they will be
absorbed by our fixed-effects model.
Our estimations control for comorbidity by using the Charlston Comorbidity Index (CCI) calculated as the sum
of the scores that are obtained for seven items, (Charlson, Pompei, Ales, & MacKenzie, 1987) adapted for SHARE
by Kusumastuti, Gerds, Lund, Mortensen, and Westendorp (2017). The share of individuals without any com-
orbidity is 20% higher among the deceased.14 Compared with survivors, the percentage of deceased respondents
that report any of these comorbidities is significantly higher for all items with the exception of arthritis and
stomach/duodenal ulcers.15
4 | EMPIRICAL STRATEGY
4.1 | Empirical specification
The sample description analysis has indicated that a significant number of respondents report to never have used HC
services, which is known to give rise to a zero-mass problem. Furthermore, the variance of HC use is higher than the
mean variance (overdispersion), resulting in highly skewed (to the right) distributions of the variables because there are
a few individuals with high consumption levels. Modelling a variable with excessive zeros and overdispersion with fixed
13Unfortunately, Wave 3 cannot be included as the questionnaire is not comparable to the other waves.
14One explanation lies in that deceased individuals with no initial comorbidities, the “End-of-Life” module reports that 33% had been sick for less
than 1 month and 21% had been sick between 1 and 6 months. Hence, the majority deathly illnesses came about in a very short interval of time (less
than 6 months).
15Tables SA2 to SA6 report the descriptive statistics of the dependent variables. Comments are reported on Appendix SA.
COSTA-FONT AND VILAPLANA-PRIETO 5
T
A
B
L
E
1
D
es
cr
ip
ti
on
of
th
e
sa
m
pl
e
In
it
ia
l
sa
m
p
le
A
ft
er
m
er
gi
n
g
co
n
se
cu
ti
ve
w
av
es
R
eg
is
te
re
d
in
at
le
as
t
th
re
e
w
av
es
N
u
m
be
r
of
ob
se
rv
at
io
n
s
N
u
m
be
r
of
ob
se
rv
at
io
n
s
N
u
m
be
r
of
in
d
iv
id
u
al
s
Su
rv
iv
or
s
D
ec
ea
se
d
T
ot
al
Su
rv
iv
or
s
D
ec
ea
se
d
T
ot
al
Su
rv
iv
or
s
D
ec
ea
se
d
T
ot
al
A
us
tr
ia
19
,1
93
11
,6
64
58
3
12
,2
47
10
,2
16
33
3
10
,5
49
3,
36
4
16
0
3,
52
4
B
el
gi
um
28
,9
31
17
,9
02
78
3
18
,6
85
15
,7
12
53
0
16
,2
42
4,
77
6
22
3
4,
99
9
C
ze
ch
R
ep
.
23
,3
02
13
,6
27
89
7
14
,5
24
12
,5
74
46
1
13
,0
35
4,
41
8
21
7
4,
63
5
D
en
m
ar
k
17
,9
12
11
,3
55
70
1
12
,0
56
10
,4
75
41
3
10
,8
88
3,
41
9
18
0
3,
59
9
E
st
on
ia
23
,7
47
14
,7
60
96
3
15
,7
23
13
,0
83
51
5
13
,5
98
4,
57
1
25
6
4,
82
7
F
ra
n
ce
23
,9
38
14
,0
53
67
4
14
,7
27
12
,3
13
38
5
12
,6
98
3,
88
5
17
5
4,
06
0
G
er
m
an
y
21
,3
57
12
,0
71
40
5
12
,4
76
10
,7
57
21
1
10
,9
68
4,
15
6
10
0
4,
25
6
G
re
ec
e
14
,5
9
5,
28
9
72
5
6,
01
4
3,
06
1
45
3
3,
51
4
1,
53
3
22
4
1,
75
7
It
al
y
24
,0
05
14
,1
87
80
0
14
,9
87
12
,5
59
51
6
13
,0
75
3,
91
3
22
6
4,
13
9
L
ux
em
bo
ur
g
4,
46
3
2,
18
7
47
2,
23
4
1,
60
5
27
1,
63
2
79
8
18
81
6
N
et
h
er
la
n
ds
12
,6
08
5,
72
4
27
7
6,
00
1
4,
25
9
11
8
4,
37
7
1,
62
2
61
1,
68
3
Po
la
n
d
10
,8
42
4,
32
1
52
8
4,
84
9
3,
75
4
21
5
3,
96
9
1,
34
6
97
1,
44
3
Po
rt
u
ga
l
4,
23
3
1,
98
9
14
4
2,
13
3
86
0
24
88
4
42
7
15
44
2
Sl
ov
en
ia
13
,8
14
7,
76
9
33
3
8,
10
2
5,
95
4
16
8
6,
12
2
2,
26
6
84
2,
35
0
Sp
ai
n
25
,9
58
15
,4
55
1,
43
4
16
,8
89
14
,1
98
84
8
15
,0
46
4,
88
1
40
3
5,
28
4
Sw
ed
en
19
,6
24
11
,7
86
82
4
12
,6
10
10
,7
37
45
5
11
,1
92
3,
61
9
23
5
3,
85
4
Sw
it
ze
rl
an
d
14
,6
28
9,
64
5
29
2
9,
93
7
9,
00
7
18
3
9,
19
0
2,
79
5
86
2,
88
1
T
ot
al
28
8,
55
5
17
5,
80
7
10
,5
29
18
6,
33
6
15
1,
12
4
5,
85
5
15
6,
97
9
51
,7
89
2,
76
0
54
,5
49
a S
ou
rc
e:
SH
A
R
E
w
av
es
(1
,2
,4
,5
,6
,a
n
d
7)
.
6 COSTA-FONT AND VILAPLANA-PRIETO
effects typically boils down to either running a negative Poisson or binomial model16 (Allison & Waterman, 2002;
Hausman, Hall, & Griliches, 1984). Recently, Winkelmann (2008) developed a double-hurdle model, and an alternative
specification used in Majo and van Soest (2011) is a zero-inflated Poisson model of a panel with only two periods. Gilles
and Kim (2017) refined this approach within a framework where the true generation process is unknown and
unobserved individual heterogeneity exists. Initially our empirical specification can be expressed as:
Yit =Xitβ+ ηi + δt + εit, ð1Þ
where Yit is the outcome variable, Xit is a vector of explanatory variables, ηi represents an individual fixed effect, δt rep-
resents a time-fixed effect, and εit absorbs the effect of other unobservable shocks that are common to all individuals.
To account for the effect of unobservables, we consider intraregional unobservable heterogeneity (at the Nomenclature
of Territorial Units for Statistics [NUTS] level), and especially, an instrumental variable approach that corrects for the
potential endogeneity of TTD. The main downside of our approach is that a linear models don't always fit a count data-
generating process well (Wooldridge, 2002). Hence, an appropriate alternative strategy is the use of a Poisson model 2.
However, if Yit is modelled as a Poisson random variable with parameter μt, it is implicitly assumed that the conditional
mean and variance of the outcome variable are equal to μt. The model is specified as follows:
E YitjXit,ηi,δt½ = exp Xitβ+ ηi + δtð Þ, ð2Þ
E Yitjμt½ =Var Y itjμt½ = μt:
Individual fixed effects (ηi) pose another problem as they cannot be purged as in linear models (i.e., first differences
or mean deviations). Hence, if we proceed to estimate the Poisson model with fixed effects, it will produce inconsistent
estimates of ηi (Neyman & Scott, 1948). However, when panel data are available, it is possible to separate the β and δt
estimates from the fixed effects estimates, which allows for retrieving consistent β and δt estimates (Blundell, Griffith, &
Windmeijer, 2002). Yet, we face the additional challenge of the potential endogeneity of the TTD problem. To address
this concern, we follow Imbens and Wooldridge (2007) and their proposed control function (CF) approach, which can
be extended to panel data. To do this, a linear regression for the TTD is first estimated using all the exogenous
TABLE 2 Dependent variables
N Mean Std. Dev Min Max
Hospitalisation during last year 156,979 0.153 0.36 0 1
Length of stay at hospital (days per year)a 24,020 11.83 20.07 1 365
Consultations with doctor/nurse during last year 156,979 0.889 0.31 0 1
Number of consultations with doctor/nurse 140,139 7.60 9.74 1 98
Stayed at nursing home 156,979 0.005 0 1
Length of stay at nursing home (weeks per year) 668 27.61 23.13 1 52
Received formal care for personal care 156,979 0.013 - 0 1
Hours receiving formal care for personal care (per year) 2,095 257.83 772.01 1 8,736
Consumed any prescribed drug (during a week)b 118,159 0.749 - 0 1
Number of prescribed drugs consumed (during a week) 118,159 2.33 1.51 1 14
Polypharmacy (5 or more prescribed drugs) 118,159 0.144 0 1
aConsidering all hospitalizations.
bThe following categories of prescribed drugs are considered: (1) high blood cholesterol, (2) high blood pressure, (3) coronary or cerebrovas-
cular diseases, (4) other heart diseases, (5) asthma, (6) diabetes, (7) joint pain or for joint inflammation, (8) other pain (e.g. headache, back
pain, etc.), (9) drugs for sleep problems, (10) anxiety or depression, (11) osteoporosis (hormonal), (12) osteoporosis (other than hormonal),
(13) stomach burns, (14) chronic bronchitis, (15) suppressing inflammation (only glycocorticoids or steroids), (16) other drugs, not yet
mentioned.
Source: SHARE waves (1, 2, 4, 5, 6, and 7).
16The Poisson model is preferred to the negative binomial because the latter does not eliminate the influence of unmeasured characteristics (Allison &
Waterman, 2002). The consistency of the fixed effects estimator is conditional on the assumption that the potential sample selection operates only
through the individual specific terms (Vella, 1998).
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regressors and the proposed instruments to obtain the residuals. Next, a Poisson model is estimated using all explana-
tory variables and residuals.17
Our panel data specification separates the two data-generating processes: an extensive margin process (probability
of the outcome being positive) and an intensive margin process (change in the outcome frequency of use). Both are
independent processes such that can be modelled using a truncated distribution (Cameron & Trivedi, 2013).18
We estimate the extensive margin following a logit model with fixed effects as below:
Pr Y it >0jXit,ηi½ =
e X itβ+ ηið Þ
1+ e Xitβ+ ηið Þ
, ð3Þ
where Yit is the outcome variable, Xit is the explanatory variable, and ηi is the unobservable heterogeneity of the individ-
ual i (i.e., the propensity of a person to use a HC service or LTC service at least once in the period). The estimation of
this model using conditional maximum likelihood is based on a restricted dataset that excludes all individuals whose
outcomes (0 or 1) do not vary throughout the period (Chamberlain, 1980).19
Next, the intensive margin is estimated using a truncated Poisson model with fixed effects in which only the positive
portion of Yit is considered as follows:
Pr Y it = jjXit,ηi½ =
e Xitγ+ ηið Þ
j
j! ee
Xit γ+ ηið Þ−1
  if Y it >0, j=1,2,… ð4Þ
We include the same explanatory variables (Xit) in both steps of the model, but there is no reason to assume that the
estimated coefficients (β and γ) will be equal. Furthermore, the unobservable individual heterogeneity (ηi) comes from
those variables (resilience, desire for independence or level of concern about diseases) that influence the use of HC ser-
vices. This model is more flexible than the Poisson model because it can model both overdispersion and
underdispersion:
Var Y itjXit,ηi½ =E YitjXit,ηi½   e Xitγ+ ηið Þ−E YitjXit,ηi½ 
 
+E YitjXit ,ηi½ : ð5Þ
If there is an excess of zeros, then Pr[Yit > 0| Xit, ηi] will be small and so will E[Yit| Xit, ηi]. Thus, the variance will be
greater than the mean (overdispersion). This is the case for hospitalisations, use of nursing home care and home care.
However, if there are few zeros, then Pr[Yit > 0| Xit, ηi] and E[Yit| Xit, ηi] will be larger, and the variance will be less than
the mean (underdispersion). This is the case for outpatient visits with a doctor or nurse and consumption of prescribed
drugs.
Estimating 4 using the maximum likelihood method does not provide consistent estimates because the individual
fixed effects cannot be separated from the model parameters. However, Majo and van Soest (2011) use a two-period
panel, and later Gillingham and Tsvetanov (2019) used an N-period panel to show that the estimates using the condi-
tional maximum likelihood can eliminate the problem of fixed effects. If the number of periods for which Yit > 0 is
17Guo and Small (2016) show that the control function (CF) estimator applied to nonlinear models is more efficient that two-stage least squares
(2SLS) provided that instrumental variables are valid. To test the convenience of the CF approach, we have estimated both models (CF and 2SLS) and
performed a Hausman test. For all variables, the null hypothesis cannot be rejected, which confirms the suitability of the CF estimator (results are
available upon request.
18We model the zero value (i.e., absence of consultations or hospitalizations, no consumption of any prescribed drug…) as a conscious decision rather
than a missing observation as it is considered in the Heckman approach. In fact, the separation between patients and not patients overcome the
requirement of an exclusion restriction which is needed in the Heckman approach in order to identify the correlation coefficient between the two
margins. An additional advantage of the two-part model is that it is robust to endogenous selection for any lower bound (zero-bound) of an outcome
variable (Drukker, 2017). To validate the suitability of modelling independent processes, we consider a test of the double-hurdle model against the
Heckman selection model and perform a Voung test, which is suitable for the case of nonnested models. For all dependent variables, the test rejects
the Heckman selection model. These results support the idea that consumption of healthcare and long-term care services follows two independent
decision paths: the decision to consume a positive amount and the decision on the extent of consumption.
19The percentage of respondents who do not change behaviour is 59.02% for hospitalisation, 64.97% for outpatient visits with doctor/nurse, 76.19% for
the probability of nursing home stays, 68.27% for the probability of receiving personal care at home and 59.72% for the probability of consuming
prescribed drugs.
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greater than or equal to two, and the explanatory variables are not constant in those periods, then, by conditioning the
likelihood function to
PT
i=1Yit , the truncated Poisson distribution does not depend on individual fixed effects, but
merely depends on explanatory variables (and time-fixed effects). In addition, Gillingham and Tsvetanov (2019) demon-
strate that when the explanatory variables are strictly exogenous, the resulting estimator is consistent.
4.2 | Endogeneity of TTD
Accounting for the endogeneity of the TTD in a truncated Poisson model remains to be addressed. Gillingham and
Tsvetanov (2019) propose an estimation procedure using the generalised method of moments (GMM), which provides
consistent estimates of the parameters. This paper uses this procedure and the STATA routine that they developed.
4.3 | Instruments
We use parents' age at death as an instrument for the TTD. More specifically, a wealth of literature indicates that a long
lifespan for a mother decreases the likelihood that her children will suffer from specific diseases, such as hypertension
or lung disease (Gjonca & Zaninotto, 2008; Goldberg, Larson, & Levy, 1996). However, other studies, such as Ikeda
et al. (2006), have found that the time of death of both the father and the mother is important, and parents' longer
lifespan decreases the probability that their children will die between the ages of 40 and 79.
The SHARE data only report maternal and paternal age at death for the deceased sample. Therefore, parental age at
death is imputed for those respondents whose parents were alive when the survey was conducted. Because age is a con-
tinuous variable, we use a multiple imputation (MI) procedure proposed by Rubin (1987) to predict the time of death of
living parents.20
4.4 | Instrument validity
To verify the validity of our instruments, we report in the Supporting information the results of a linear regression for
the TTD using these instruments, the other explanatory variables and the year fixed effects (Table SB2). The four pro-
posed instruments are significant with the effect of a mother's age at death being larger for both men and women. Each
father's additional year of life implies an increase in the TTD of 0.22 days for men and 0.09 days for women (0.29 and
0.17, respectively, for an additional year of life of mother). Taking into account the average life expectancy21 in the EU
in 2017, offspring's TTD would be between 17.43 and 22.86(7.92 and 14.02) days later for men (women). We also show
that TTD decreases for men alongside lower educational levels, however, it increases with wealth, in smaller
municipalities.22
20We use both the information from the Main Questionnaire (MQ) and from the End-of-Life Questionnaire (EoLQ) for each one of the SHARE waves.
The necessary requirements to apply MI are the following ones. First, missing data must be random. This requirement is satisfied in our dataset
because age at death is missing for all parents who are still alive by the time the respondent (adult children) answer the survey. Second, the variables
with missing values we are trying to impute must be explained by other variables that do not have missing values. In our dataset, parents' age of
decease can be predicted from other variables for which we have complete information (see Appendix SB for a detailed explanation of these variables
and the result of the MI).
21According to Eurostat statistics, life expectancy at birth in the European Union (EU) was estimated to be 80.9 years in 2017, reaching 83.5 years for
women and 78.3 years for men.
22Table SB3 displays the direct effect of the instruments on the outcome variables and confirms that the instruments are not correlated with
unobserved variables affecting the dependent variables at a 5% significance. The exception being the probability of hospitalisation. We are concerned
with respect to idiosyncratic heterogeneity, which arises when some of the explanatory variables are correlated with time-varying unobserved shocks.
Following Card (1999), the correlation between the instrument and the dependent variable through the unobservables can give rise to bias in IV
estimates. To address this issue Lin and Wooldridge (2019) propose a test for idiosyncratic exogeneity based on the robustness properties of the
Poisson fixed-effects estimator combined with the control function approach, that is robust to distributional misspecification and serial dependence.
First, we estimate a fixed effects model and retrieve the fixed effects residuals. Second, we use a Poisson fixed effects model over the mean function
and test the significance of the residuals through a Wald test. Applying this procedure to all the dependent variables, we conclude that the null of no
idiosyncratic endogeneity cannot be rejected (results available upon request)
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One potential threat to the identification, is the presence of intergenerational transmission of lifestyles, namely, that
behaviours that shorten parent's life expectancy are more likely to be adopted by their children, who would also experi-
ence a reduction of TTD. To address this specific concern, we have regressed the effect of parents' age at death, as well
as other explanatory variables, over the probability of having sedentary lifestyles, being overweight, having ever smoked
daily, being a smoker at present time, and having consumed at least one alcoholic beverage during the last 7 days (-
Table SB4). Overall, our results suggest that the effect of parent's age at time of death over TTD is not channelled
through potential inherited habits from parents. Finally, although genetics are still important, we do not expect a signif-
icant estimate change in later life overall, and they woud be absorved by a FE estimator.23
5 | RESULTS
5.1 | Baseline results
Table 3 reports the results of the logit model with fixed effects for the probability of using HC (extensive margin) and
the truncated Poisson model for the duration of HC or the number of visits (intensive margin). Both margins were esti-
mated using five different specifications. The first set of estimates (M1–M3 specifications) are not estimated using
instrumental variables (IV) and consider a different set of controls as follows:.specification M1 includes individual spe-
cific controls (age, age squared, marital status, income, and wealth adjusted by the number of household members)
alongside spatial controls such as the size of the municipality of residence, the availability of health care resources by
NUTS, and year fixed effects.24 Next, we add TTD (proximity to death) in the M2, and CCI in the M3 specification. M4
and M5 specifications report the effect of the same explanatory variables as before but correcting TTD with an instru-
mental variable (IV) strategy (CF for logit with fixed effects and a GMM truncated Poisson). To ease the interpretation,
marginal effects are reported in the logit specification, and the incidence risk-ratio is reported in the truncated Poisson
specification. Our estimates come from clustered robust standard errors (at the NUTS level) with 100 bootstrap
replications.
5.2 | Extensive margin
Estimates reported in the M5 specification suggest that TTD and CCI have opposite effects (negative for the former and
positive for the latter) for the extensive margin (probability) of hospitalisation, as well as the probability of nursing
home stays, home care, and prescription drug consumption. Comparing the M2 and M4 estimates for the probability of
hospitalisation, we identify an increase in the effect of age (from 0.005 to 0.117) and TTD (from −0.016 to −0.376).
Hence, we conclude that IV estimates correct for the underestimation of the two-reference variable. Yet, even more
importantly, the magnitude of the TTD coefficient declines to one-seventh (−0.054) of its previous value when we con-
trol for comorbidities in M5. We find that a closer TTD reduces the likelihood of hospitalisation, but an increase in CCI
increases the likelihood of hospitalisation. It is important to note that, as expected, controlling for comorbidities using
CCI (in M5) significantly reduces the effect of ageing. Without CCI, an additional year of life increased the probability
of hospitalisation by 11.7 percentage points, whereas after controlling for CCI, an additional year of life only increased
this probability by 1.4 percentage points.
When examining the extensive margin of outpatient care with a doctor and nurse, we find that IV estimates result
in a series of changes in the relevant estimates. First, age is no longer a significant variable, indicating that ageing does
not increase outpatient visits to a doctor or nurse. Second, the positive effect of the TTD increases (from 0.001 to 0.042).
Therefore, visiting a doctor or nurse is primarily driven by TTD and the presence of comorbidities, especially the latter.
23We have reestimated the logit and truncated models for the subsample of respondents whose parents had already deceased by the time of the survey
to account for the possibility that deceased parents transmit the worst characteristics to their children. However, estimated coefficients for age, TTD
and CCI do not show significant differences.(results are available upon request).
24Descriptive statistics are shown on Table SA7. Specifically, the number of hospital beds per 100,000 inhabitants is included in the probability of
hospitalisation and length of stay at the hospital. The number of beds in nursing and residential care facilities per 100,000 inhabitants in the
regressions for the probability of staying in a nursing home and length of stay. Finally, the number of doctors and nurses per 100,00 inhabitants is
included in the probability of outpatient visits and number of outpatient visits with doctor/nurse. For those individuals whose region of residence is
unknown we have applied the country average.
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TABLE 3 Marginal effects reported for logit part; incidence rate ratios reported (Truncated Poisson model)
Logit (marginal effects)
Exogenous TTD TTD (IV)
M1 M2 M3 M4 M5
Hospitalisation Hospitalisation (extensive margin)
Age 0.001(0.001) 0.005***(0.001) 0.0001(0.001) 0.117***(0.002) 0.014***(0.005)
Age2 0.000***(0.000) −0.000**(0.000) 0.0001*(0.0005) −0.001***(0.000) −0.000** (0.000)
TTD −0.016***(0.000) −0.013***(0.000) −0.376***(0.004) −0.054***(0.015)
CCI 0.074***(0.001) 0.066***(0.003)
Resid first stage 0.363***(0.004) 0.042***(0.015)
Constant −0.013(0.030) 0.019(0.030) 0.159***(0.029) 0.704***(0.031) 0.223***(0.037)
N 156,979 156,979 156,979 156,979 156,979
Log-likelihood −62,829.0 −61,333.0 −59,872.7 −58,447.2 −57,055.6
AIC 125,737.9 122,744.1 119,821.7 116,968.8 114,183.8
BIC 126,136.5 123,133.3 120,201.5 117,339.6 114,545.8
Chi2 259.069 376.764 981.128 935.454 906.317
Outpatient visit Doctor/nurse outpatient visit (extensive margin)
Age 0.014***(0.001) 0.014***(0.001) 0.010***(0.001) 0.089***(0.001) −0.003 (0.004)
Age2 −0.000***(0.000) −0.000***(0.000) −0.000***(0.000) −0.001***(0.000) 0.000 (0.000)
TTD −0.001**(0.000) 0.001***(0.000) −0.241***(0.004) 0.042***(0.013)
CCI 0.051***(0.001) 0.058***(0.003)
Resid first stage 0.242***(0.004) −0.041***(0.013)
Constant 0.292***(0.026) 0.293***(0.026) 0.389***(0.026) 0.750***(0.027) 0.327***(0.033)
N 156,979 156,979 156,979 156,979 156,979
Log-likelihood −48,406.3 −47,253.8 −46,128.7 −45,030.4 −43,958.3
AIC 96,892.7 94,585.7 92,333.7 90,135.2 87,989.2
BIC 97,291.2 94,974.8 92,713.5 90,506.0 88,351.1
Chi2 267.389 243.466 599.165 555.220 553.854
Stays nursing home Nursing home stays (extensive margin)
Age −0.004***(0.000) −0.003***(0.000) −0.003***(0.000) −0.001***(0.000) −0.002*(0.001)
Age2 0.000***(0.000) 0.000***(0.000) 0.000***(0.000) 0.000***(0.000) 0.000*(0.000)
TTD −0.002***(0.000) −0.002***(0.000) −0.008***(0.001) −0.006** (0.003)
CCI 0.001***(0.000) 0.0003**(0.001)
Resid first stage 0.006***(0.001) 0.004 (0.003)
Constant 0.111***(0.006) 0.115***(0.006) 0.117***(0.006) 0.126***(0.006) 0.124***(0.007)
N 156,979 156,979 156,979 156,979 156,979
Log-likelihood −3,734.2 −3,645.3 −3,558.5 −3,473.8 −3,391.1
AIC 7,548.5 7,368.8 7,193.3 7,022.0 6,854.9
BIC 7,947.0 7,757.8 7,573.1 7,392.8 7,216.8
Chi2 189.305 236.533 220.782 220.925 203.962
Personal care Home care (extensive margin)
Age 0.022***(0.000) 0.020***(0.000) 0.021***(0.000) 0.026***(0.001) 0.028***(0.002)
Age2 0.000***(0.000) 0.000***(0.000) 0.000***(0.000) 0.000***(0.000) 0.000***(0.000)
TTD −0.010***(0.000) −0.009***(0.000) −0.095***(0.002) −0.049***(0.008)
CCI 0.017***(0.000) 0.009***(0.001)
Resid first stage 0.086***(0.002) 0.040***(0.008)
Constant 0.670***(0.016) 0.706***(0.016) 0.734***(0.016) 0.864***(0.016) 0.794***(0.020)
N 156,979 156,979 156,979 156,979 156,979
Log-likelihood −7,964.6 −7,774.9 −7,589.8 −7,409.1 −7,232.7
AIC 16,001.1 15,620.2 15,248.3 14,885.2 14,530.8
BIC 16,334.1 15,945.1 15,565.5 15,194.9 14,833.1
Chi2 1,007.573 1,078.357 1,114.884 1,113.728 1,031.372
Any prescribed drug Prescription drug consumption (extensive margin)
Age 0.048***(0.001) 0.049***(0.001) 0.041***(0.001) 0.236***(0.002) 0.185***(0.005)
Age2 −0.000***(0.000) −0.000***(0.000) −0.000***(0.000) −0.002***(0.000) −0.001***(0.000)
TTD −0.005***(0.000) 0.000(0.000) −0.007***(0.005) −0.009***(0.017)
CCI 0.117***(0.001) 0.032***(0.003)
Resid first stage 0.607***(0.005) 0.449***(0.017)
Constant −1.273***(0.035) −1.264***(0.035) −1.043***(0.034) −0.118***(0.035) −0.355***(0.042)
N 156,979 156,979 156,979 156,979 156,979
Log-likelihood −72,245.1 −70,525.0 −68,845.8 −67,206.6 −65,606.5
AIC 144,570.2 141,128.1 137,767.9 134,487.7 131,285.6
BIC 144,968.7 141,517.1 138,147.6 134,858.4 131,647.5
Chi2 1,783.305 1,631.050 2,793.264 2,854.246 2,643.527
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When we turn to nursing home use, we observe a positive and linear effect of age, but TTD (proximity to death)
reduces (increases) the probability of nursing home care use. That is, nursing home care is more commonly used by
individuals closer to death. That said, when our estimates are corrected using an IV strategy, the effect of the TTD is
four times larger (increases from −0.002 to M2 to −0.008 in M4). However, when CCI is controlled for in M5, the effect
of TTD decreases by 25% (until −0.006). The positive effect of CCI exceeds the negative effect of age in absolute value.
Next, the extensive margin of home care use is examined using the same strategy, our IV strategy produces a TTD
coefficient that is almost 10 times larger than before (from −0.010 in M2 to −0.095 in M3), which reinforces the idea
that TTD is underestimated when omitted variable bias and reverse causality are adjusted for. However, the effect
decreases by half when CCI is included (−0.049). This supports the idea that the need for home care decreases with
proximity to death and the existence of comorbidities. Notice that TTD refers to proximity to death, hence a negative
coefficient means that HC utilisation increses with time to death.
Lastly, when comparing the medication consumption in the M2 and M4 estimates, we find that the IV estimation
amplifies the positive effect of age (from 0.049 to 0.236) and amplifies the negative effect of TTD (from −0.005 to
−0.607). Both effects decrease when CCI is introduced in M5, and the effect of age on the probability of consuming
medicine decreases by 5%.
The extensive margin of the probability of five or more medicines (polypharmacy) is then estimated using a sample
that is limited to individuals who consume at least one form of medication. When comparing M2 and M4, we find that
the effect size of TTD increases considerably. In M2, an additional year closer to death produces a barely perceptible
decrease in the probability of consuming five or more medications. In contrast, in M4, each year closer to death
decreases this probability by 14.7%. Finally, the inclusion of CCI in M5 suggests that an additional comorbidity
increases the probability of polypharmacy by 12.6%, but the TTD variable is no longer significant and the effect of age
declines by 2%.
5.3 | Intensive margin
M5 model specification, reveals that TTD and CCI exhibit opposite effects on length of hospital stay, on the number of
doctor or nurse outpatient visits, and on the number of prescription drugs consumed. An additional comorbidity
increases the probability that a hospital stay will extend by an additional day by 15.3%. Likewise, it increases the
TABLE 3 (Continued)
Logit (marginal effects)
Exogenous TTD TTD (IV)
M1 M2 M3 M4 M5
Polypharmacy Probability of consuming 5 or more prescribed drugs
Age 0.011***(0.001) 0.012***(0.001) 0.004***(0.001) 0.024***(0.001) 0.004***(0.001)
Age2 −0.000***(0.000) −0.000***(0.000) −0.000**(0.000) −0.000***(0.000) −0.000***(0.000)
TTD −0.015***(0.001) 0.001(0.001) −0.147***(0.004) −0.002 (0.004)
CCI 0.126***(0.001) 0.126***(0.001)
Resid 1st stage 0.042***(0.001) 0.001 (0.001)
Constant −0.406***(0.037) −0.390***(0.037) −0.216***(0.034) −0.208***(0.037) −0.213***(0.035)
N 118,159 118,159 118,159 118,159 118,159
Log-likelihood −42,410.5 −41,400.8 −40,415.0 −39,452.8 −38,513.4
AIC 84,901.1 82,879.6 80,906.3 78,979.9 77,099.5
BIC 85,299.6 83,268.7 81,286.1 79,350.7 77,461.4
Chi2 225.750 216.604 1.990.125 289.298 1.837.066
Note: This table reports different specifications of age, TTD, and morbidity effect on health care use on both the intensive and extensive margin. M1 includes as
explanatory variables age, age squared, marital status, income, and wealth adjusted by the number of household members, municipality size, health care
resources by NUTS, and year fixed effects. TTD is included in the M2 model. CCI is included in the M3 model. M4 and M5 contain the same explanatory
variables as M2 and M3, except that IV is used for TTD (CF for logit with fixed effects and a GMM truncated Poisson). Marginal effects are offered for the logit
models, and the incidence risk ratio is shown for the truncated Poisson models. Clustered robust standard errors (at the NUTS level) with 100 bootstrap
replications are obtained in all models.
*Statistically significant at 10%.
**Statistically significant at 5%.
***Statistically significant at 1%.
12 COSTA-FONT AND VILAPLANA-PRIETO
TABLE 3 Continued
Truncated Poisson (IRR)
Exogenous TTD TTD (IV)
M1 M2 M3 M4 M5
Hospitalisation Length of stay at hospital (days per year)
Age 1.031**(0.013) 1.054***(0.013) 1.034***(0.013) 1.053***(0.013) 1.023*(0.013)
Age2 1.000(0.000) 1.000***(0.000) 1.000**(0.000) 1.000***(0.000) 1.000(0.000)
TTD 0.828***(0.008) 0.847***(0.009) 0.840***(0.035) 0.951***(0.034)
CCI 1.146***(0.013) 1.153***(0.013)
Resid first stage
Constant 2.674**(1.213) 2.962**(1.347) 4.619***(2.119) 2.911**(1.361) 4.055***(1.893)
N 24,020 24,020 24,020 24,020 24,020
Log-likelihood −218,658.6 −213,452.4 −208,370.2 −203,409.0 −198,566.0
AIC 437,397.2 426,983.0 416,816.7 406,892.5 397,204.6
BIC 437,720.7 427,298.8 417,125.0 407,193.5 397,498.4
Chi2 111.811 483.975 773.145 487.113 757.891
Outpatient visit Doctor/nurse outpatient visit (intensive margin)
Age 1.015**(0.007) 1.030***(0.007) 1.004(0.006) 1.057***(0.008) 0.999 (0.006)
Age2 1.000(0.000) 1.000***(0.000) 1.000(0.000) 1.000***(0.000) 1.000(0.000)
TTD 0.876***(0.006) 0.911***(0.006) 0.658***(0.026) 0.953** (0.018)
CCI 1.307***(0.011) 1.310***(0.011)
Resid first stage
Constant 3.078***(0.688) 3.375***(0.767) 6.559***(1.349) 4.992***(1.164) 6.189***(1.270)
N 140,139 140,139 140,139 140,139 140,139
Log-likelihood −664,679.6 −648,853.9 −633,405.0 −618,323.9 −603,601.9
AIC 1,329,439.0 1,297,785.7 1,266,886.0 1,236,722.1 1,207,276.3
BIC 1,329,833.0 1,298,170.3 1,267,261.5 1,237,088.6 1,207,634.1
Chi2 305.588 498.450 1.048.862 700.224 1.075.492
Stays nursing home Nursing home stays (weeks per year)
Age 0.865***(0.005) 0.867***(0.005) 0.884***(0.005) 0.859***(0.005) 0.877***(0.005)
Age2 1.001***(0.000) 1.001***(0.000) 1.001***(0.000) 1.001***(0.000) 1.001***(0.000)
TTD 0.967***(0.004) 0.963***(0.004) 1.073***(0.014) 1.034** (0.014)
CCI 0.910***(0.005) 0.914***(0.005)
Resid first stage
Constant 5,740***(1,222.08) 6,133***(1,307.23) 3,323***(717.62) 5,542***(1,182.57) 3,193***(690.08)
N 668 668 668 668 668
Log-likelihood −7,647.2 −7,465.1 −7,287.3 −7,113.8 −6,944.5
AIC 15,374.3 15,008.3 14,650.9 14,302.1 13,961.6
BIC 15,553.5 15,183.1 14,821.6 14,468.7 14,124.2
Chi2 572.234 623.327 917.038 690.499 947.197
Personal care Home care (hours per year)
Age 1.092***(0.001) 1.072***(0.001) 1.072***(0.001) 1.132***(0.001) 1.136***(0.001)
Age2 1.000***(0.000) 1.000***(0.000) 1.000***(0.000) 0.999***(0.000) 0.999***(0.000)
TTD 1.237***(0.001) 1.237***(0.001) 0.706***(0.002) 0.696***(0.002)
CCI 1.003***(0.001) 1.080***(0.001)
Resid first stage
Constant 2.888***(0.112) 2.347***(0.091) 2.363***(0.092) 4.407***(0.172) 4.234***(0.165)
N 2,095 2,095 2,095 2,095 2,095
Log-likelihood −232,886.3 −227,341.4 −221,928.5 −216,644.5 −211,486.3
AIC 465,832.7 454,741.4 443,914.3 433,344.9 423,027.1
BIC 465,984.6 454,889.7 444,059.0 433,486.2 423,165.1
Chi2 330,768.242 385,346.242 385,358.220 439,649.931 440,320.107
Any prescribed drug Prescription drug consumed (drugs per week)
Age 1.066***(0.003) 1.072***(0.003) 1.039***(0.003) 1.125***(0.003) 1.039***(0.003)
Age2 1.000***(0.000) 1.000***(0.000) 1.000***(0.000) 0.999***(0.000) 1.000***(0.000)
TTD 0.951***(0.003) 0.998(0.003) 0.562***(0.006) 0.990 (0.009)
CCI 1.395***(0.002) 1.394***(0.002)
Resid first stage
Constant 0.122***(0.011) 0.124***(0.011) 0.253***(0.023) 0.248***(0.022) 0.256***(0.023)
N 118,159 118,159 118,159 118,159 118,159
Log-likelihood −170,029.2 −165,980.9 −162,029.0 −158,171.1 −154,405.1
AIC 340,138.3 332,039.8 324,134.1 316,416.6 308,882.9
BIC 340,525.5 332,417.8 324,503.0 316,776.8 309,234.5
Chi2 12,103.814 12,449.715 48,742.386 15,111.931 48,743.353
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probability that an outpatient visit will increase by 31% and increases the probability of consuming additional medica-
tion by 39.4%. In contrast, a one-year increase in the TTD decreases the probability that a hospital stay will be extended
for another day by 4.9%. Similarly, TTD also decreases the probability of an additional outpatient visit by 4.7% and the
probability of consuming an additional medication by 1%. When we turn to examine the effect of age, we find that
including CCI in M5 attenuates the effect of age. We find that each additional year of life only increases the probability
of an additional day of hospitalisation by 2.3% compared to 5.3% as reported in M4 (without CCI).
We find that TTD produces the largest effect on home care use. A one-year increase in TTD decreases the probabil-
ity of receiving an additional hour of personal care by 30.4%. Moreover, increasing CCI increases the probability of per-
sonal care by 8%. In some cases, the inclusion of the Charlson comorbidity index (CCI) significantly decreases the effect
of TTD. For example, TTD effect decreases (from −16% to −4.9%) the length of hospital stay, and (from −34.2% to
−4.7%) the number of doctor/nurse consultations. When we examine the effect of length of stay in t nursing home, and
the hours of home care, we find a decrease of a smaller magnitude. Finally, when we examine the the number of pre-
scribed drugs, we find that TTD ceases to be significant when controlling for CCI (in estimates with and without IV).
M5 estimates suggest that each year of additional life only increases the probability of large medication consumption by
3.9% which compares to 12.5% estimate in M4 (without including CCI).
25So the effect we are interested is the effect of age above the effect of CCI. Co-morbidities might change over time with behavioral change
irrespective of ageing.
TABLE 3 (Continued)
Truncated Poisson (IRR)
Exogenous TTD TTD (IV)
M1 M2 M3 M4 M5
Polypharmacy
Age
Age2
TTD
CCI
Resid 1st stage
Constant
N
Log-likelihood
AIC
BIC
Chi2
Note: This table reports different specifications of age, TTD, and morbidity effect on health care use on both the intensive and extensive mar-
gin. M1 includes as explanatory variables age, age squared, marital status, income, and wealth adjusted by the number of household mem-
bers, municipality size, health care resources by NUTS, and year fixed effects. TTD is included in the M2 model. CCI is included in the M3
model. M4 and M5 contain the same explanatory variables as M2 and M3, except that IV is used for TTD (CF for logit with fixed effects and
a GMM truncated Poisson). Marginal effects are offered for the logit models, and the incidence risk ratio is shown for the truncated Poisson
models. Clustered robust standard errors (at the NUTS level) with 100 bootstrap replications are obtained in all models.
*Statistically significant at 10%.
**Statistically significant at 5%.
***Statistically significant at 1%.
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5.4 | Ageing effects
We find that each additional year of life has a positive effect on the length of hospital stay (+2.3%) and on the number
of medications consumed (+3.9%). This effect is six and ten times lower respectively, than the effect of an additional
comorbidity. The significance of CCI emerges when examining the number of outpatient care use, because age ceases
FIGURE 1 Predicted outcomes conditioned on age, time to death, and Charlston Comorbidity Index (CCI). Charlston Comorbidity
Index: Level 6 also includes Level 7. In the graphs for the probability of hospitalisation: The probability for time to death (TTD;
13–24 months) overlaps with probability for TTD (+3 years). In the graphs for length of stay at hospital: length of stay for TTD
(0–12 months) overlaps with length of stay for TTD (13–24 months). In the graphs for the predicted probability of consultation: The
probability for TTD (13–24 months) overlaps with the probability for TTD (25–36 months) [Colour figure can be viewed at
wileyonlinelibrary.com]
COSTA-FONT AND VILAPLANA-PRIETO 15
to be significant once CCI is introduced25. Moreover, we estimate that an additional year of life decreases the length of
stay in nursing homes by 13%. The largest impact of age corresponds to the frequency of home-based assistance for per-
sonal care because each additional year increases the probability of receiving one more hour by 13.6%.
Figure 1 depicts the predicted probability and duration of HC use as a function of the age cohort, TTD, and the
value of the Charlson Comorbidity Index (CCI). We show that the probability of hospitalisation exhibits no change with
TTD, but quadruples with a six-fold increase in CCI (when it varies from 0 to 6/7). In contrast, the length of a hospital
stay reduces with TTD and increases as CCI rises, but the probability of an outpatient visit with a doctor/nurse consul-
tation in the last year is higher for a TTD of more than 3 years. However, the number of consultations is lower for a
TTD of more than 3 years compared to shorter TTD horizons. Figure 1 shows that the probability of a nursing home
stay reaches a 40–50% magnitude among the 75–84 and 85+ age cohorts, with the maximum levels of comorbidity and
FIGURE 1 (Continued)
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close to death (TTD within 0–12 months). In contrast, it is almost zero for a TTD of more than 3 years and for all age
cohorts and CCI values, and the length of stay exhibits a U-shaped curve for all TTD horizons. The difference in proba-
bility for home care use (for personal care) by TTD exhibits the largest effect among the 75–84 and 85+ age cohorts,
with large CCI and reaches the maximum when TTD falls in the 0–12 month range. When we turn to examine the
number of hours of care received, we find a significant rise in the number of formal caregiving hours for CCI = 5, and
then it decreases for CCI = 6. Finally, the probability of medicine consumption is greater than 50% for all age cohorts
(80% after the age of 75). As CCI increases, the probability of consuming one medication or of consuming 5 or more
medicines (polypharmacy) is close to one for all age cohorts.
5.5 | Robustness checks
5.5.1 | Comparison between truncated Poisson and truncated negative binomial
Table SC1 compares the estimated odds ratios obtained from a truncated Poisson specification (the same shown in
Table 3) and those obtained when count data variables are modelled using a truncated negative binomial. Although the
sign and significance of the estimated coefficients are the same in both estimations, the magnitude of the effect is
always higher when a negative binomial model is used. For example, a one unit increase in CCI raises the probability
that the number of outpatient visits increases between 40.9% (truncated negative binomial) and 31% (truncated
Poisson).26 Nonetheless, the economic explanation underpinning our results is satisfied regardless of the estimator.
5.5.2 | Attrition
Given that our estimates could be biased by potential non-random selection of the final sample, Table SC2 compares
the outcome variables of the initial sample and the final sample. Test statistics for equality of means between samples
do not reject the null hypothesis of equal means for all variables. We have also conducted a test for attrition suggested
by Verbeek and Nijman (1992) which involves the estimation of all the cross-sections introduced as an explanatory vari-
able, a binary indicator that takes the value 1 in case that the individual is present in the final sample, and 0 otherwise.
Results are shown on Tables SC3 (binary outcomes) and SC4 (count data variables). The variable “present in all sam-
ples” is only significant for the probability of nursing home use and length of stay. Although the effect on the probabil-
ity of nursing home stay is small (1.3 pp.), the effect on the length of stay is larger (e.g., being in the final sample
increases the probability that duration of stay rises by 1 week with 14.4%). Hence, we conclude that attrition does not
diminish the validity of our estimations.
5.6 | Instrument validity
In order to dispel any cloud of doubt surrounding the instrument (parent's age at death) used, and to show that the
causal inferences about TTD on health care outcomes are credible, we rely on a two bound method, originally proposed
by Conley, Hansen, and Rossi (2012) that allows to obtain inferences even when the instrumental variables do not sat-
isfy the exogeneity restriction (see Appendix SD for explanation of both approaches). Figure SD1 shows the results of
for the instrument “male & father's age of decease” (similar results have been obtained for the other instruments;
results available upon request). The solid line represents the 2SLS father's age of death effect estimate for the respective
outcome variable. The two dash lines represent the upper and lower limits of the respective test scores. Overall, the
results confirm that even with substantial deviation from the exclusion restriction, the instrument still has a consider-
able effect over the outcome variable.27
26On the other hand, the comparison of the information criteria (AIC and BIC) and the log-likelihood indicates that the truncated Poisson
outperforms the negative binomial for all the dependent variables (i.e., smaller information criteria and higher log-likelihood).
27In the right column figures for union of confidence intervals are presented. The x axis measures how strong does the violation of the exclusion
restriction needs to be in order for the instrument to turn insignificant. In all figures, the confidence intervals do not include the value 0 (red line), so
we can infer that the IV estimations are robust to possible violations of the exclusion restriction
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5.7 | Effect of CCI over estimations
To verify the model fit after controlling for CCI, Figure SE1 compares the residuals from the logit and truncated Poisson
models (using IV for CCI) conditioned on including CCI or not, that is, comparing M4 with M5. For all regressions,
residuals are significantly lower in the models with CCI which confirms the overperformance of M5.
6 | HETEROGENEITY
Finally, in this section, we study whether results are driven by specific groups of people or countries. All the models are
re-estimated for men and women and for two groups of countries.
6.1 | Gender differences
Table SA8 displays the descriptive statistics for outcome variables, and Table SE1 reports the model estimation results.
A 1-year increase in the TTD decreases both, the probability of hospitalisation and hospital length of stay, more inten-
sively for men than for women (−3.9 pp. vs. −2.5 pp. for the probability and −5.2% vs. −3.1% for length of stay). Some-
times, the effect is more intense for women: (a) a 1-year increase in the TTD decreases the probability of one additional
outpatient visit with a doctor/nurse by 4.8% for men and by 10.1% for women and (b) a 1-year increase in the TTD
decreases the probability of receiving one additional hour of home care by 21.2% for men and 32.2% for women.
We estimate that each additional CCI increases the probability of receiving an additional hour of personal care by
3% among men and 10.6% among women, but decreases the probability of extending the duration of stay at a nursing
home by 1 week in 12.1% among men and 5.5% among women. When we turn o the effect of age, we find a large effect
size for the number of prescribed medicines consumed: an additional year of life increases the probability of consuming
one additional prescribed drug by 2.6% among men, and 5.8% among women.
Figure SE2 depicts the predicted probabilities and predicted values of count data variables broken down by gender,
TTD, and CCI. It is worth noting that hospital length of stay increases significantly from the age of 75 (for high CCI,
irrespectively of TTD). In contrast, the length of stay at a nursing home describes a U shape, with a minimum length
for the cohort age 75–84 years (regardless CCI and TTD). The number of home care hours exhibits a substantial jump
in the oldest cohort. Finally, we find that as an individual ages, the higher TTD is, and the steeper the probability of
consuming any prescribed drug (for low CCI).
6.2 | Northern and Southern European countries
Next, we test whether there is a North-South effect by selecting four northern countries (Denmark, Estonia, Poland,
and Sweden) and three southern countries (Greece, Italy, and Spain). Table SA9 shows the descriptive statistics for a
number of outcome variables, and Table SE3 displays the model estimation results. The most striking result is the dif-
ferent impact of CCI on the probability of hospital use (and length of stay), which turns out to be two (three) percentage
points lower in southern countries than in the northern countries. Consistently, the effect of ageing on hospitalisations
is smaller in the southern countries. In northern countries, each additional year of life increases the likelihood that
hospitalisation will be extended by 1 day by 13.5% compared to an 11.2% estimate in southern countries. Furthermore,
in both groups of countries, TTD predicts the probability of hospitalisation, but not for length of stay.
As previously, the probability and the number of an outpatient visits with a doctor or nurse decrease with TTD. A
one-year leap towards death increases the number of outpatient visits by 12.8% in southern countries and 8.2% in north-
ern countries. Another significant difference between both country groups is in the effect of CCI, which is larger in
southern countries. An increase in CCI by one unit, increases the probability of an outpatient visit in 6.9 percentage
points in southern countries and in 5.1 percentage points in northern countries. Consistently, a one unit increase in
CCI increases the number of outpatient visits in 34.3% in southern countries and in 29.1% in northern countries. The
estimates for home care are interesting as well. The probability of receiving formal care at home increases slightly with
TTD for both country groups. However, TTD's effect on the number of formal, in-home care hours is different for each
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country group. A 1-year step towards death increases the provision of personal care by 1 hour (+26.1% in southern
countries and +16.9% in northern countries).
There are significant differences in the effects of age, TTD, and CCI on medication use. (a) One year of life increases
the probability of medicine consumption by five percentage points in northern countries versus an increase of 3.8 per-
centage points in southern countries. (b) In contrast, an increase by one additional year in the TTD, decreases the
amount of medicine consumed by 2.8% (and the probability of polypharmacy with a sample limited to individuals who
consume at least one medicine by 7.1 percentage points) in northern countries versus 12.2% (10.8 percentage points) in
southern countries. (c) Each unit increase in comorbidity in CCI increases the probability of polypharmacy by 13.6 per-
centage points in northern countries compared with 11.4 percentage points in southern countries.
Figure SE4 in the Supporting information shows the predicted probabilities and predicted counts for the analysed
outcomes based on the age cohort, the TTD (differentiating between the two extremes of 0–12 months and 3+years),
and CCI (considering only very low comorbidity profiles (CCI = 0.1) and very high profiles (CCI = 5, 6, or 7). The prob-
ability of hospitalisation and the length of hospital stay are higher for northern countries. In contrast, the probability of
an outpatient visit with a doctor or nurse is higher for northern countries only when CCI is low. It is higher for a TTD
of 0–12 months and decreases slightly for both groups of countries for the 85+ age cohort. In contrast, the number of
outpatient visits, is higher in southern countries, and a high CCI increases the gap between both groups. Furthermore,
for both countries, a greater proximity to death is associated with fewer outpatient visits. When we turn to home care,
we find differences among northern countries for a TTD of more than 3 years, a high CCI, and after the age of 75.
Finally, when we examine medication consumption, the picture is drastically different depending on morbidity
controls.
7 | CONCLUSION
This paper studies the effect of ageing on HC utilisation to disentangle the effect of ageing from other determinants of
HC utilisation. We exploit longitudinal individual end of life data that measures the effect of TTD. We control for and
measure a number of comorbidities and consider the endogeneity of TTD.
Our estimates suggest that, as predicted by the ‘red herring’ hypothesis, proximity to death increases hospitaliza-
tions, length of hospital stay, LTC use (home and nursing home care), and outpatient care use. More importantly, we
document that the effect size of proximity to death exceeds that of an extra year of life. However, our estimates are het-
erogeneous across different types of HC. More specifically, we find that ageing does not increase the utilisation of out-
patient care. Furthermore, the effect of ageing is attenuated when we include comorbidity controls in explaining both
the extensive and intensive margin of hospitalizations and medicine consumption. One potential explanation lies in
that physicians discriminate patients based on their age.28 Although we cannot directly observe such behaviour in our
data (e.g., we ignore access to elective surgical procedures, specific diagnosis, decisions to manage patients on intensive
care units or on general wards), our results are not consistent with ‘ageist practices’29.
These results taken together indicate that estimates of the effect of ageing on HC utilisation are attenuated, or
become insignificant, when alternative explanations of an ageing effect such as endogenous TTD and the influence of
comorbidities, as well as omitted variable bias, are accounted for. The effect of ageing on HC use seems to be simulta-
neously affected by several red-herrings.
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